Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study assessing HEMO-CAR-T therapy

X
Trial Profile

A phase 1 study assessing HEMO-CAR-T therapy

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HEMO-CAR-T cell therapy-Hemogenyx (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Hemogenyx
  • Most Recent Events

    • 25 Apr 2024 According to a Hemogenyx Pharmaceuticals media release, the Company announced that an Investigational New Drug ("IND") application submitted in May 2023 seeking authorisation from the U.S. Food and Drug Administration ("FDA") to begin a Phase I clinical trial of HEMO-CAR-T for treating acute myeloid leukaemia (AML). The Company is now proceeding to the next step in the development of HEMO-CAR-T, the commencement of Phase I clinical trials.
    • 29 Feb 2024 event According to a Hemogenyx Pharmaceuticals media release, The funds US Dollar 4.2 million (3.325 million pounds ) have been raised to allow the Company to progress HEMO-CAR-T to phase 1 clinical trials.
    • 09 Feb 2024 Status changed from suspended to planning, according to a Hemogenyx Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top